Gentry Leesa has filed 4 insider transactions across 1 company since March 2024.
Most recent transaction: a grant/award of 128550 shares of RenovoRx, Inc. ($RNXT) on April 03, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| April 3, 2026 | RenovoRx, Inc. | $RNXT | Gentry Leesa | Chief Clinical Officer | A | Stock Option | 128550 | $0.00 | 128,550.0000 | 36,649,916 | 9999.99% | 0.35% |
| July 1, 2025 | RenovoRx, Inc. | $RNXT | Gentry Leesa | Chief Clinical Officer | A | Stock Option | 6619 | $0.00 | 6,619.0000 | 36,546,752 | 9999.99% | 0.02% |
| April 14, 2025 | RenovoRx, Inc. | $RNXT | Gentry Leesa | Chief Clinical Officer | A | Stock Option | 26477 | $0.00 | 26,477.0000 | 36,546,752 | 9999.99% | 0.07% |
| March 6, 2024 | RenovoRx, Inc. | $RNXT | Gentry Leesa | Chief Clinical Officer | A | Options | 190000 | $0.00 | 190,000.0000 | 0 | 9999.99% | 0.00% |